We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Beckman Coulter Adopts Verification System

By Labmedica staff writers
Posted on 21 Jul 2006
The Artel MVS (multichannel verification system), developed by Artel (Westbrook, Maine, USA), has been adopted by Beckman Coulter (Fullerton, CA, USA), leading manufacturer of testing instrumentation, in order to verify the accuracy and precision of its automated liquid handling systems used in pharmaceutical and clinical laboratories. More...


A future option to the company's Biomek customers, the MVS will provide documentation about system performance, aiding labs to meet compliance and regulatory requirements. The MVS will be part of the company's Field Service Operational Qualification Program.

Because Biomek customers quickly generate data used in critical assays and due to increasing regulatory pressure governing process controls, Beckman Coulter wanted a more convenient method to measure instrument performance. Upgrading its Field Service Operational Qualification Program technology with the MVS, a rapid and traceable system, allows Beckman Coulter to easily meet customer demands for documented validation.

Artel's MVS allows us to rapidly assess the performance of our instruments in the field and provide documented, traceable data, notes Lisa Knapp, technical services manager for Beckman Coulter. This is especially important for some of our customers operating in regulated environments who need third-party validation of instrumentation and processes.

The MVS is based on proprietary ratiometric photometry, which measures light absorption by two specially formulated dyes in order to verify volume, making it especially effective at low volumes. In addition, the MVS can perform calibration very quickly, and can be applied to Beckman Coulter's full portfolio of Biomek liquid handlers, ranging from one to 384 channels.

The MVS is becoming the tool of choice for laboratory liquid delivery quality assurance, noted Ms. Knapp. We equipped our service representatives with a standard performance measurement tool so they can communicate in the same language with Artel's customers using the MVS on the bench, and this will streamline service visits. Robust and unaffected by environmental conditions, the MVS is portable and user-friendly, facilitating its use by service representatives in the field as well as by end-users for interim checks.



Related Links:
Artel
Beckman Coulter

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Analyzer
respons® UDS100
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.